Loxoprofen sodium oral sustained-release preparation as well as preparation and application thereof
By using a combination of water-soluble and water-insoluble polymers in oral preparations of loxoprofen sodium, the release degree is adjusted, and the problems of short duration of drug efficacy and large fluctuations in blood drug concentration are solved, and the slowness of loxoprofen sodium is achieved The stable release of tablets and long-term analgesic effects reduce the frequency of dosing and the risk of side effects.
Patent Information
- Application Number
- CN202411249829.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-06
- Publication Date
- 2024-11-08
AI Technical Summary
The efficacy of the existing oral preparation of loxoprofen sodium is short and the blood concentration fluctuates greatly, resulting in frequent administration of patients, increasing the risk of gastrointestinal side effects.
Using the combination of water-soluble and water-insoluble polymers to regulate the release of oral sustained-release preparations of loxoprofen sodium, by controlling the proportion and content of ingredients, prepare loxoprofen sodium sustained-release tablets that meet the requirements to reduce blood medicines. Concentration fluctuates, prolonging the duration of treatment.
It achieves stable release of loxoprofen sodium sustained-release tablets, reduces the number of doses, reduces fluctuations in blood drug concentration, and reduces the risk of adverse reactions. It is suitable for maintaining analgesic effects for a long time.
Smart Images

Figure CN118903033A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of pharmaceutical preparations, and in particular relates to the field of preparation of oral controlled-release preparations. Background Art
[0002] Loxoprofen Sodium, chemical name is monosodium salt 2-{4-[(2-oxocyclopentyl)methyl]phenyl}propionate sodium dihydrate. Most NSAIDs inhibit the synthesis of prostaglandins (PG) in the body, that is, by binding to cyclooxygenase, masking the active center of the enzyme, thereby blocking the enzyme from catalyzing the metabolism of arachidonic acid into PG, exerting analgesic, anti-inflammatory and antipyretic effects. The structural formula is as follows:
[0003]
[0004] As a new type of NSAIDs, loxoprofen sodium is different from other drugs in that it is a prodrug and has no activity itself. It becomes active only after being rapidly converted into a trans-OH body by the liver, thus reducing damage to the gastrointestinal tract. The trans-OH body (SRS coordination) can block the generation of cyclooxygenase and prevent the biosynthesis of prostaglandins, thereby producing anti-inflammatory and analgesic effects. Loxoprofen sodium has excellent analgesic and anti-inflammatory effects, characterized by strong analgesic effects, anti-inflammatory and antipyretic effects similar to other similar drugs, and weak activity against chronic inflammation. Its analgesic effect is 10 to 20 times stronger than similar drugs such as ketoprofen, indomethacin, and naproxen, with rapid onset and strong, balanced analgesic, anti-inflammatory, and antipyretic effects; it is rapidly absorbed after oral administration and distributed in the liver, kidneys, and plasma at a high concentration, and then most of it becomes a gluconic acid conjugate of the original or a gluconic acid conjugate of the hydroxylated form, which is mainly excreted rapidly through urine, and no drug accumulation is found. The half-lives (t 1 / 2 ) were 1.22±0.07h, 1.31±0.05h, and 0.90±0.08h, respectively, and the individual differences were relatively small.
[0005] The oral dosage forms of loxoprofen sodium currently on the market include tablets, capsules, dispersible tablets, granules, oral solutions, and fine granules, all of which are immediate-release dosage forms and need to be administered three times a day. In addition, sustained-release enteric-coated tablets have been launched in South Korea. From its formulation patent (KR100798730B1), it can be known that the tablet core has a certain sustained-release effect, with a drug-containing specification of 40 mg. The tablet core is coated with an enteric layer, and the enteric layer contains a drug-containing immediate-release layer, with a drug-containing specification of 50 mg. The dosage form of this product is designed as follows: first, the first peak concentration of the immediate-release layer will appear rapidly in the body, and then the second peak concentration of the sustained-release core will be formed after the enteric layer is dissolved; the first peak of the enteric-coated sustained-release tablet reaches its peak faster than that of the ordinary tablet, and the peak concentration (4.95ug / ml) is 30% higher than that of the ordinary tablet (3.80ug / ml). The risk of side effects of long-term use of the sustained-release enteric-coated tablet is relatively high; after the enteric coating is ruptured, the core layer drug is completely released within 1 hour, and the second peak concentration of sustained release will be formed in 3-4 hours. The absorption of all drugs is completed within 4 hours. For patients with persistent pain, the analgesic effect in the 6-12 hour period is difficult to guarantee; and the preparation process is relatively complicated, including the preparation of sustained-release tablet cores, enteric layer coating, immediate-release layer coating, and finally film layer coating. The process steps are long, and the drug coating rate of the drug layer is difficult to guarantee.
[0006] In summary, the oral preparations of loxoprofen sodium currently on the market include tablets, capsules, dispersible tablets, granules, oral solutions, etc. These oral preparations have the following shortcomings in clinical use: ① The half-life of loxoprofen sodium is relatively short, and the half-life of loxoprofen sodium and its active metabolites (t 1 / 2 ) are 1.22±0.07h and 1.31±0.05h respectively; frequent administration is required to maintain the efficacy of the drug, and 3-4 doses a day are required to achieve the therapeutic effect, and patient compliance is low. Even so, the large fluctuation in blood drug concentration affects the analgesic effect, and the decrease in blood drug concentration, especially at night, causes pain to reappear, affecting the patient's quality of life; ② NSAIDs inhibit cyclooxygenase (COX) while exerting anti-inflammatory and analgesic effects, but also inhibit cyclooxygenase (COX-1) with gastrointestinal physiological protective effects, thereby causing gastrointestinal side effects. If the drug is released quickly in the gastrointestinal tract, the local excessive drug concentration will irritate the gastric mucosa. The peak blood drug concentration caused by multiple administrations is more likely to cause gastrointestinal side effects and increase the risk of adverse reactions. Summary of the invention
[0007] In view of the problems of large fluctuations in blood drug concentration and short duration of drug effect of existing oral preparations of loxoprofen sodium, the first object of the present invention is to provide an oral sustained-release preparation of loxoprofen sodium, aiming at controlling the drug release rate.
[0008] The second purpose of the present invention is to provide a method for preparing the loxoprofen sodium oral sustained-release preparation, aiming to obtain the loxoprofen sodium oral sustained-release preparation with the release rate meeting the requirements and with small fluctuation of blood drug concentration, thereby reducing side effects and prolonging the duration of therapeutic effect.
[0009] The third object of the present invention is to provide the use of the loxoprofen sodium oral sustained-release preparation in the preparation of drugs for treating analgesic, anti-inflammatory and antipyretic diseases.
[0010] An oral sustained-release preparation of loxoprofen sodium, comprising, by weight percentage: 20-35% of loxoprofen sodium and 11-71% of a sustained-release material;
[0011] The sustained-release material comprises a water-soluble polymer and selectively comprises a water-insoluble polymer, wherein the content of the water-soluble polymer in the loxoprofen sodium oral sustained-release preparation is 10-70%, and the content of the water-insoluble polymer is less than 15%.
[0012] In the present invention, the water-soluble polymer is at least one of hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, carboxymethyl cellulose, methyl cellulose, polyethylene oxide, sodium alginate, and a mixture of polyvinyl acetate and povidone.
[0013] In the present invention, the water-insoluble polymer is carbomer or ethyl cellulose.
[0014] The present invention shows that the release rate of the loxoprofen sodium oral sustained-release preparation can be adjusted by controlling the contents of the water-soluble polymer and the water-insoluble polymer.
[0015] Preferably, the sustained-release material comprises a water-soluble polymer and a water-insoluble polymer. Studies have shown that a better synergistic effect of the components can be obtained under the preferred ratio, which helps to further optimize the release behavior of the preparation and further reduce its release fluctuation.
[0016] Preferably, in the oral sustained-release preparation of loxoprofen sodium, the content of the water-soluble polymer is 10-70%, preferably 25-45%, and more preferably 35-45%; the content of the water-insoluble polymer is 0.5-15%, further 1-15%, further 1-10%, and further 1-5%.
[0017] The present invention shows that the innovative combination of water-soluble polymers and water-insoluble polymers, combined with the joint control of the ratio and content of the two, can unexpectedly achieve synergy, unexpectedly adapt to the molecular structure of loxoprofen sodium, unexpectedly improve the release rate of the sustained-release preparation, and reduce the fluctuation of blood drug concentration.
[0018] In the present invention, the loxoprofen sodium oral sustained-release preparation further comprises 6-50% of a filler and 2-5% of a binder.
[0019] In the present invention, the filler is at least one of microcrystalline cellulose, pregelatinized starch, calcium hydrogen phosphate, anhydrous calcium hydrogen phosphate, magnesium trisilicate, and magnesium aluminum silicate.
[0020] In the present invention, the binder is at least one of povidone, copovidone, hydroxypropyl cellulose, methyl cellulose, hypromellose and ethyl cellulose.
[0021] Preferably, the loxoprofen sodium oral sustained-release preparation further comprises other excipients in an amount of less than 5%.
[0022] In the present invention, the other auxiliary materials are at least one of lubricants, glidants, flavors, flavoring agents, and pigments.
[0023] In the present invention, in the loxoprofen sodium oral sustained-release preparation, the weight portion of the loxoprofen sodium is 20 to 35 parts, the weight portion of the sustained-release material is 11 to 71 parts; the weight portion of the filler is 6 to 50 parts; the weight portion of the binder is 2 to 5 parts; and the weight portion of the other auxiliary materials is less than or equal to 5 parts.
[0024] Preferably, the water-soluble polymer is hypromellose, and the water-insoluble polymer is carbomer. Studies have shown that the preferred ingredients can exhibit better synergy and can further reduce the release fluctuation of the preparation.
[0025] In the present invention, the loxoprofen sodium oral sustained-release preparation is a sustained-release tablet in which each component is homogeneously mixed.
[0026] In the present invention, the loxoprofen sodium oral sustained-release preparation is a single-layer sustained-release tablet containing the component mixture.
[0027] In the present invention, the loxoprofen sodium oral sustained-release preparation has release amounts of 20%-45%, 40%-90% and more than 80% of the labeled amount in 1 hour, 4 hours and 10 hours, respectively.
[0028] Preferably, the loxoprofen sodium oral sustained-release preparation has a release amount of 20%-40%, 40%-85% and more than 80% of the labeled amount in 1 hour, 4 hours and 10 hours, respectively.
[0029] The invention also provides a method for preparing the loxoprofen sodium oral sustained-release preparation, which is obtained by mixing various components.
[0030] The present invention can further cite the preparation method, which comprises premixing loxoprofen sodium, sustained-release material, filler and binder, granulating, wet granulating, drying, dry granulating, mixing with other auxiliary materials, and then pressing and molding to obtain the product.
[0031] The present invention also provides the use of the loxoprofen sodium oral sustained-release preparation in the preparation of a medicine having at least one of analgesic, anti-inflammatory and antipyretic effects.
[0032] The present invention also provides the use of the loxoprofen sodium oral sustained-release preparation in preparing a medicine for treating at least one of osteoarthritis, low back pain and shoulder periarthritis.
[0033] Beneficial Effects
[0034] 1. The loxoprofen sodium sustained-release tablets developed by the present invention can unexpectedly achieve synergistic effects by further controlling the proportion and content of the sustained-release materials in combination, thereby improving the release stability and reducing the release fluctuation. In addition, the components can regulate the sustained-release behavior, making it unexpectedly meet the bioavailability requirements.
[0035] 2. The loxoprofen sodium sustained-release tablets developed by the present invention have a single peak concentration release in vivo pharmacokinetics, a stable blood drug concentration, and can gradually release active substances. The peak concentration is reached about 4 hours after taking the medicine. The continuous absorption phase can prolong the plasma concentration of the active ingredient in the systemic circulation, and is suitable for long-term maintenance treatment of persistent pain. Compared with ordinary preparations, sustained-release tablets reduce the number of dosing times and have good patient compliance.
[0036] 3. The preparation process of the loxoprofen sodium sustained-release tablets developed by the present invention is simple and controllable, and is convenient for industrial production.
[0037] 4. The loxoprofen sodium sustained-release tablets developed by the present invention have smaller fluctuations in blood drug concentration than the commercially available loxoprofen sodium tablets, and the lower blood drug concentration greatly reduces the risk of adverse reactions. It is suitable for clinical needs of analgesia, anti-inflammatory and antipyretic, and will not add extra burden to patients. It is also suitable for long-term medication for patients with chronic diseases such as osteoarthritis, low back pain, and shoulder periarthritis. BRIEF DESCRIPTION OF THE DRAWINGS
[0038] Figure 1 Example 6-Drug-time curves of human prototype drugs (loxoprofen sodium sustained-release tablets (T) and loxoprofen sodium tablets (R));
[0039] Figure 2 Example 6 - Drug-time curves of active metabolites in humans (loxoprofen sodium sustained-release tablets (T) and loxoprofen sodium tablets (R));
[0040] Figure 3Example 6-Drug-time curve of the original drug for Beagle dogs (loxoprofen sodium sustained-release tablets (T) and loxoprofen sodium tablets (R));
[0041] Figure 4 Example 6 - Drug-time curves of active metabolites in Beagle dogs (loxoprofen sodium sustained-release tablets (T) and loxoprofen sodium tablets (R));
[0042] Figure 5 Examples 15-16-Drug-time curves of human prototype drugs (loxoprofen sodium sustained-release tablets (T1, T2) and loxoprofen sodium tablets (R));
[0043] Figure 6 Examples 15-16 - Drug-time curves of active metabolites in humans (loxoprofen sodium sustained-release tablets (T1, T2) and loxoprofen sodium tablets (R));
[0044] Figure 7 Example 17-Drug-time curve of the original drug for Beagle dogs (loxoprofen sodium sustained-release tablets (sustained-release preparation group) and loxoprofen sodium tablets (conventional preparation group));
[0045] Figure 8 Example 17-Drug-time curve of active metabolites in Beagle dogs (loxoprofen sodium sustained-release tablets (sustained-release preparation group) and loxoprofen sodium tablets (conventional preparation group));
[0046] Fig. 9 Comparative Example 1-Drug-time curve of human prototype drug (loxoprofen sodium sustained-release tablets (T) and loxoprofen sodium tablets (R));
[0047] Fig.10 Comparative Example 1 - Drug-time curves of active metabolites in humans (loxoprofen sodium sustained-release tablets (T) and loxoprofen sodium tablets (R)). DETAILED DESCRIPTION
[0048] In order to make the purpose, technical solutions and advantages of the present invention more clearly understood, the present invention will be further described in detail through examples below. The following examples are only used to explain the present invention and do not represent the scope of protection of the present invention. The scope of protection of the present invention shall be subject to the claims.
[0049] The reagents and raw materials used in the present invention are all commercially available. The loxoprofen sodium tablets used are commercially available, and the license holder is Daiichi Sankyo Pharmaceutical (Shanghai) Co., Ltd. (trade name: Specification: 60mg).
[0050] 1. Experimental methods
[0051] 1.1 Release
[0052] Use 900 ml of phosphate buffer (take 6.8 g of potassium dihydrogen phosphate and 0.9 g of sodium hydroxide, dissolve and dilute to 1000 ml with water, shake well, and adjust the pH to 6.8 with sodium hydroxide or phosphoric acid) as the release medium, the rotation speed is 100 revolutions per minute, and the dissolution and release rate determination method (Method 1, Part 4 of the Chinese Pharmacopoeia 2020 Edition 0931) is used for determination. Take 5 ml of the dissolution solution at 1 hour, 4 hours and 10 hours respectively, filter, and immediately replenish the release medium of the same volume and temperature.
[0053] Limit 1: The release of each tablet in 1 hour, 4 hours and 10 hours should be 20%-45%, 40%-90% and more than 80% of the labeled amount respectively, all of which should comply with regulations.
[0054] Limit 2: The release of each tablet in 1 hour, 4 hours and 10 hours should be 20%-40%, 40%-85% and more than 80% of the labeled amount respectively, all of which should comply with regulations.
[0055] 1.2 Pharmacokinetic drug-time curve
[0056] (1) Human body
[0057] The drug exposure was investigated by comparing the oral administration of self-made loxoprofen sodium sustained-release tablets (test preparation T, specification: 90 mg) twice a day (once every 12 hours, 1 tablet each time) and loxoprofen sodium tablets (reference preparation R) three times a day (once every 8 hours, 1 tablet each time) in the fasting state; venous blood was collected before the first dose (0h) and at different time points after the first dose.
[0058] (2)Beagle dog
[0059] Beagle dogs that passed the quarantine were selected, half male and half female, and were orally administered with homemade loxoprofen sodium sustained-release tablets (test preparation T, specification: 90 mg) twice a day (once every 12 hours, 1 tablet each time) and loxoprofen sodium tablets (reference preparation R) 3 times a day (once every 8 hours, 1 tablet each time) (each administration was delivered with 10 mL of water, fasting for more than 12 hours before administration, unified feeding 4 hours after administration, and unified water 1 hour after administration). Venous blood samples from the four limbs were collected before the first administration (0 hour) and at different time points after the first administration to detect the concentrations of loxoprofen and its active metabolites in the plasma of Beagle dogs.
[0060] The specific embodiments of the present invention are as follows:
[0061] The tablet of the present invention may have the following composition ratios by weight:
[0062]
[0063]
[0064] In the following cases, as typical examples, the water-soluble polymer is hydroxypropyl methylcellulose or hydroxypropyl cellulose or sodium alginate; the water-insoluble polymer is carbomer homopolymer type A 971P, with a viscosity range of 4000-11000 mPa.s.
[0065] Examples 1-18
[0066] 1. Preparation formula composition
[0067] Table 1 Prescription composition of Examples 1-18
[0068]
[0069] Note: The sustained-release material of Example 15 is a single hydroxypropyl methylcellulose, and the content of hydroxypropyl methylcellulose is 36%. Example 16 uses ethyl cellulose to replace carbomer, and the content of hydroxypropyl methylcellulose is 35%, and the content of ethyl cellulose is 1%. Example 17 uses SR (polyvinyl acetate povidone mixture) replaces hypromellose, The SR content is 35%, and the carbomer content is 1%. In Example 18, the sustained-release material contains 35.5% hydroxypropyl methylcellulose and 0.5% carbomer.
[0070] 2. Preparation process
[0071] (1) Premixing: Mix loxoprofen sodium, microcrystalline cellulose, sustained-release material, and povidone K30 uniformly;
[0072] (2) Granulation: adding purified water to the material in step (1) in the form of atomization, and subjecting the material to high shear to fully granulate;
[0073] (3) Wet granulation: Use a sieve to wet granulate the soft material;
[0074] (4) drying the material in step (3) in an oven or a fluidized bed;
[0075] (5) Dry granulation: the dried granules obtained in step (4) are sieved for dry granulation;
[0076] (6) Total mixing: uniformly mixing the material from step (4) and magnesium stearate;
[0077] (7) The total mixed granules of step (5) are compressed into tablets to obtain loxoprofen sodium sustained-release tablets.
[0078] 3. Release
[0079] Table 2 Release test results of Examples 1-18
[0080]
[0081] Examples 1-18 are loxoprofen sodium sustained-release tablets with loxoprofen sodium accounting for 20%-35%. The release results show that the combined use of water-soluble polymers and water-insoluble polymers can well control drug release: when the amount of water-soluble polymer is 10%-70% and the amount of water-insoluble polymer is 0%-15%, the release meets the limit requirement 1; when the amount of water-soluble polymer is 10%-70% and the amount of water-insoluble polymer is 1%-15%, the release meets the limit requirement 2. The difference between Examples 12-14 and Example 6 is only that the water-soluble polymers in the sustained-release material are different: the amount of carbomer remains unchanged, and Examples 12, 13, and 14 replace hydroxypropyl methylcellulose with equal amounts of hydroxypropyl cellulose, sodium alginate, and polyethylene oxide, respectively, and the release meets the requirements.
[0082] Example 6 Pharmacokinetic drug-time curve results of self-made sample loxoprofen sodium sustained-release tablets (T) and commercially available loxoprofen sodium tablets (R) in human body (see Figure 1 and Figure 2 ) showed that compared with loxoprofen sodium tablets, the half-life of loxoprofen sodium and its active metabolites in plasma of the sustained-release tablet group was t 1 / 2 , peak time T max Prolongation; Peak concentration of loxoprofen sodium and its active metabolites in plasma C max The pharmacokinetics of Example 6 in Beagle dogs (see Figure 3 and Figure 4 ) The results were basically consistent with human pharmacokinetic data.
[0083] Example 15: Compared with Example 6, the difference is that the sustained-release material does not contain carbomer, but only contains 36% of hydroxypropyl methylcellulose. The release rate of Example 15 is between limits 1 and 2. The results of the drug-dose curves of the homemade sample loxoprofen sodium sustained-release tablets (T1) and the commercially available loxoprofen sodium tablets (R) in the human body (see Figure 5 and Figure 6 ) shows that compared with the commercially available loxoprofen sodium tablets, the drug peak concentration C of loxoprofen sodium and its active metabolites in Example 15 is max Slightly lower, trough concentration equivalent, Example 15 Half-life of loxoprofen sodium and its active metabolites in plasma t 1 / 2 , peak time T max extend.
[0084] Example 16: Compared with Example 6, the difference is that in the sustained-release material, carbomer is replaced by an equal amount of ethyl cellulose, and the amount of hydroxypropyl methylcellulose remains unchanged. The release rate of Example 16 is between limits 1 and 2. The results of the in vivo drug-delivery curves of the homemade sample loxoprofen sodium sustained-release tablets (T2) and the commercially available loxoprofen sodium tablets (R) in the human body (see Figure 5 and Figure 6) shows that compared with the commercially available loxoprofen sodium tablets, the drug peak concentration C of loxoprofen sodium and its active metabolites in Example 16 max Slightly lower, trough concentration equivalent, Example 16 Half-life of loxoprofen sodium and its active metabolites in plasma t 1 / 2 , peak time T max extend.
[0085] Example 17: Compared with Example 6, the difference is that in the sustained-release material, the hypromellose is replaced by an equal amount of a polyvinyl acetate-povidone mixture ( SR), the amount of carbomer remains unchanged. The release rate of Example 17 is between limits 1 and 2. From the pharmacokinetics in Beagle dogs (see Figure 7 and Figure 8 ), the half-life t of the sustained-release tablets (sustained-release preparation group) prepared in Example 17 and the loxoprofen sodium tablets (conventional preparation group) 1 / 2 , peak time T max Extension, C max quite.
[0086] Example 18: Compared with Example 6, the difference is that in the sustained-release material, the total amount of the hypromellose and carbomer is 36%, but the amount of hypromellose is 35.5%, and the amount of carbomer is 0.5%.
[0087] The release degree of Example 18 is between limits 1 and 2.
[0088] Comparative Example 1
[0089] Compared with Example 9, the difference is that in the sustained-release material, the amount of hypromellose is 9%, and the amount of carbomer is 16%.
[0090] The release results showed that the release rate was significantly reduced, especially the release was incomplete after 10 hours.
[0091] Comparative Example 1 The results of the in vivo drug-dose curves of the self-made sample loxoprofen sodium sustained-release tablets (T) and the commercially available loxoprofen sodium tablets (R) in the human body (see Fig. 9 and Fig.10 ) showed that the peak concentration of the second administration of Comparative Example 1 was significantly higher than the peak concentration of the first administration, indicating that the drug release was slow and some of the active ingredients of the first administration took effect during the second administration.
[0092] Table 3 Comparative Example 1 Prescription Composition
[0093] composition Weight percentage (%) Loxoprofen Sodium 30 Microcrystalline Cellulose 42 Hydroxypropyl methylcellulose 9 Carbomer 16 Povidone K30 2 Magnesium Stearate 1 total 100
[0094] Note: In Comparative Example 1, the content of hypromellose is less than 10%, and the content of carbomer is greater than 15%.
[0095] Table 4 Comparative Example Release Determination Results (%)
[0096]
[0097] By comparing the release data in Tables 2 and 4, it can be seen that the use of the sustained-release components of the combination of the present invention, combined with the joint control of the content and ratio of the two, can achieve synergy and optimize the release behavior of the preparation.
Claims
1. A loxoprofen sodium oral sustained-release preparation, characterized in that Contains 20-35% loxoprofen sodium and 11-71% sustained-release material; The sustained-release material comprises a water-soluble polymer and selectively comprises a water-insoluble polymer, wherein the content of the water-soluble polymer in the loxoprofen sodium oral sustained-release preparation is 10-70%, and the content of the water-insoluble polymer is less than 15%.
2. The loxoprofen sodium oral sustained-release preparation according to claim 1, wherein The sustained-release material comprises a water-soluble polymer and a water-insoluble polymer; Preferably, in the loxoprofen sodium oral sustained-release preparation, the content of the water-soluble polymer is 10-70%, preferably 25-45%, and more preferably 35-45%; the content of the water-insoluble polymer is 0.5-15%, further 1-15%, further 1-10%, and further 1-5%.
3. The loxoprofen sodium oral sustained-release preparation according to claim 1, characterized in that The water-soluble polymer is at least one of hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, carboxymethyl cellulose, methyl cellulose, polyethylene oxide, sodium alginate, and a polyvinyl acetate-povidone mixture; and the water-insoluble polymer is carbomer or ethyl cellulose.
4. The loxoprofen sodium oral sustained-release preparation according to claim 1, wherein It also contains 6-50% filler, 2-5% binder, Preferably, the composition further comprises other auxiliary materials with a content of less than 5%, wherein the other auxiliary materials are at least one of lubricants, glidants, flavors, correctives and pigments.
5. The loxoprofen sodium oral sustained-release preparation according to any one of claims 1 to 4, characterized in that The loxoprofen sodium oral sustained-release preparation is a sustained-release tablet in which each component is uniformly mixed.
6. The loxoprofen sodium oral sustained-release preparation according to claims 1 to 5, characterized in that: Its release in 1 hour, 4 hours and 10 hours is 20%-45%, 40%-90% and more than 80% of the labeled amount respectively; Preferably, the release amounts in 1 hour, 4 hours and 10 hours are 20%-40%, 40%-85% and more than 80% of the labeled amount, respectively.
7. A method for preparing the loxoprofen sodium oral sustained-release preparation according to any one of claims 1 to 6, characterized in that: The ingredients are mixed to obtain.
8. The method for preparing the loxoprofen sodium oral sustained-release preparation as claimed in claim 7, wherein The ingredients are premixed, granulated, dried, sized, mixed with other auxiliary materials, and then pressed into shape to obtain the product.
9. Use of the loxoprofen sodium oral sustained-release preparation according to any one of claims 1 to 6 in the preparation of a medicament having at least one of analgesic, anti-inflammatory and antipyretic effects.
10. Use of the loxoprofen sodium oral sustained-release preparation according to any one of claims 1 to 6 in the preparation of a medicament for treating at least one of osteoarthritis, low back pain and scapulohumeral periarthritis.
